Uterine Adenosarcoma: a Review

Adenosarcomas are rare malignancies of the female genital tract, accounting for approximately 5 % of uterine sarcomas. Occasionally, adenosarcoma occurs in the ovaries or in extra-uterine tissue, which may be related to endometriosis. These tumors are characterized by benign epithelial elements and a malignant mesenchymal component. Pathologic diagnosis is dependent on the identification of the characteristic morphologic features. The most common immunohistochemical markers for adenosarcoma are CD10 and WT1, but these are not specific. The most frequent presenting symptom is abnormal uterine bleeding. The majority of patients present with stage I disease, with a 5-year overall survival of 60 to 80 %. Survival is influenced by the presence of myometrial invasion, sarcomatous overgrowth, lymphovascular invasion, necrosis, and the presence of heterologous elements including rhabdomyoblastic differentiation. Patients with sarcomatous overgrowth have significantly increased risk of recurrence 23 versus 77 % and decreased 5-year overall survival 50 to 60 %. Standard of care treatment is total hysterectomy with bilateral salpingo-oophorectomy without lymphadenectomy, as the incidence of lymph node metastasis is rare. Retrospective data does not support the use of adjuvant pelvic radiotherapy in uterine adenosarcomas as no survival benefit is seen. Insufficient data exists to recommend routinely neoadjuvant or adjuvant chemotherapy for uterine adenosarcomas. Limited evidence exists for the role of hormonal therapy in uterine adenosarcomas. The PIK3/AKT/PTEN pathway is mutated in ∼70 % of adenosarcomas, and this may represent a possible therapeutic target. This article reviews the current state of knowledge concerning uterine adenosarcoma and discusses the management of this rare tumor. Similar content being viewed by others

Papers of particular interest, published recently, have been highlighted as: •• Of major importance Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, et al. Prognostic factors in early-stage uterine sarcoma. Gynecol Oncol Group Study Cancer. 1993;71(4 Suppl):1702–9. D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116(1):131–9. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol. 2004;93(1):204–8. Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54(3):355–64. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol. 1990;21(4):363–81. Shi Y, Liu Z, Peng Z, Liu H, Yang K, Yao X. The diagnosis and treatment of Mullerian adenosarcoma of the uterus. Aust N Z J Obstet Gynaecol. 2008;48(6):596–600. Benito V, Lubrano A, Arencibia O, Andujar M, Alvarez E, Medina N, et al. Clinicopathologic analysis of uterine sarcomas from a single institution in the Canary Islands. Int J Gynaecol Obstet. 2009;107(1):44–9. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus. A clinicopathologic analysis of ten cases of a distinctive type of Mullerian mixed tumor. Cancer. 1974;34(4):1138–49. Kaku T, Silverberg SG, Major FJ, Miller A, Fetter B, Brady MF. Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases. Int J Gynecol Pathol. 1992;11(2):75–88. Blom R, Guerrieri C. Adenosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53 and mdm-2 analysis of 11 cases. Int J Gynecol Cancer. 1999;9(1):37–43. Chin PS, Chia YN, Lim YK, Yam KL. Diagnosis and management of Mullerian adenosarcoma of the uterine cervix. Int J Gynaecol Obstet. 2013;121(3):229–32. Tanner EJ, Toussaint T, Leitao Jr MM, Hensley ML, Soslow RA, Gardner GJ, et al. Management of uterine adenosarcomas with and without sarcomatous overgrowth. Gynecol Oncol. 2013;129(1):140–4. Krivak TC, Seidman JD, McBroom JW, MacKoul PJ, Aye LM, Rose GS. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival. Gynecol Oncol. 2001;83(1):89–94. Clement PB, Scully RE. Extrauterine mesodermal (Mullerian) adenosarcoma: a clinicopathologic analysis of five cases. Am J Clin Pathol. 1978;69(3):276–83. Clement PB. Mullerian adenosarcomas of the uterus with sarcomatous overgrowth. A clinicopathological analysis of 10 cases. Am J Surg Pathol. 1989;13(1):28–38. Clement PB, Scully RE. Mullerian adenosarcomas of the uterus with sex cord-like elements. A clinicopathologic analysis of eight cases. Am J Clin Pathol. 1989;91(6):664–72. •• Carroll A, Ramirez PT, Westin SN, Soliman PT, Munsell MF, Nick AM, et al. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence. Gynecol Oncol. 2014;135(3):455–61. Largest single institution series of uterine adenosarcoma patients which showed that the presence of sarcomatous overgrowth was associated with a higer risk of recurrence. Bernard B, Clarke BA, Malowany JI, McAlpine J, Lee CH, Atenafu EG, et al. Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival. Gynecol Oncol. 2013;131(3):634–9. Gallardo A, Prat J. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol. 2009;33(2):278–88. Verschraegen CF, Vasuratna A, Edwards C, Freedman R, Kudelka AP, Tornos C, et al. Clinicopathologic analysis of Mullerian adenosarcoma: the M.D. Anderson Cancer Center experience. Oncol Rep. 1998;5(4):939–44. Arend R, Bagaria M, Lewin SN, Sun X, Deutsch I, Burke WM, et al. Long-term outcome and natural history of uterine adenosarcomas. Gynecol Oncol. 2010;119(2):305–8. Carleton C, Houghton OP, McCluggage WG. Juvenile granulosa cell tumor arising in ovarian adenosarcoma: an unusual form of sarcomatous overgrowth. Hum Pathol. 2015;46(4):614–9. Czernobilsky B, Gillespie JJ, Roth LM. Adenosarcoma of the ovary. A light- and electron-microscopic study with review of the literature. Diagn Gynecol Obstet. 1982;4(1):25–36. Garalejic E, Arsic B, Perovic M, Vasiljevic M, Usaj SK, Stanojevic D. Adenosarcoma ovarii in a 51-year-old woman: case report. Eur J Gynaecol Oncol. 2012;33(5):543–5. Hirakawa E, Yamamoto Y, Fujimoto C, Kobayashi S, Haba R, Ishikawa M, et al. Aggressive adenosarcoma of the ovary. Histopathology. 2003;42(2):202–3. Litta P, Pozzan C, Sacco G, Merlin F, Saccardi C, Ambrosini A. Adenosarcoma of the ovary. A case report. Eur J Gynaecol Oncol. 2004;25(4):507–8. Manipadam MT, Munemane A, Emmanuel P, McCluggage WG. Ovarian adenosarcoma with extensive deciduoid morphology arising in endometriosis: a case report. Int J Gynecol Pathol. 2008;27(3):398–401. Mikami M, Tanaka K, Onouchi M, Komiyama S, Ishikawa M, Hirose T. A case of ovarian adenosarcoma with a heterologous rhabdomyosarcoma component: a brief case report. Eur J Obstet Gynecol Reprod Biol. 2004;117(1):112–4. Shah A, Rekhi B, Maheshwari A, Jambhekar NA. Low-grade Mullerian adenosarcoma with prominent decidualization, involving bilateral ovaries against a background of endometriosis: a diagnostic and treatment challenge. J Postgrad Med. 2013;59(2):149–52. Shetty M, Lal N, Vu NH. Mullerian adenosarcoma of the ovary: case report and review of the literature. Ultrasound Q. 2007;23(3):189–91. Kao GF, Norris HJ. Benign and low grade variants of mixed mesodermal tumor (adenosarcoma) of the ovary and adnexal region. Cancer. 1978;42(3):1314–24. Fukunaga M, Nomura K, Endo Y, Ushigome S, Aizawa S. Ovarian adenosarcoma. Histopathology. 1997;30(3):283–7. Chen ZW, Saad RS. Ovarian adenosarcoma arising from benign cystadenoma and associated intraoperative consultation pitfalls. Int J Gynecol Pathol. 2010;29(5):415–8. Chen YL, Hsiao SM, Lin MC, Lin HH. Bone metastasis as the initial presentation in one case of ovarian cancer with two components of endometrioid adenocarcinoma and adenosarcoma. Taiwan J Obstet Gynecol. 2009;48(3):298–301. Giarenis I, Peat D, Nieto JJ. Combined malignant ovarian tumour consisting of angiosarcoma, adenosarcoma, cystadenofibroma and granulosa cell tumour. J Obstet Gynaecol. 2008;28(1):121–3. Hirakawa E, Kobayashi S, Miki H, Haba R, Saoo K, Yamakawa K, et al. Ascitic fluid cytology of adenosarcoma of the ovary: a case report. Diagn Cytopathol. 2001;24(5):343–6. Lee TY, Lee C, Choi WJ, Lee JY, Kim HY. Synchronous occurrence of primary malignant mixed mullerian tumor in ovary and uterus. Obstet Gynecol Sci. 2013;56(4):269–72. Patel T, Gupta A, Trivedi P, Shah M. Osteoid differentiation in mesodermal (mullerian) adenosarcoma of ovary. J Cancer Res Ther. 2013;9(3):529–31. Petrovichev NN. Mesodermal (Muller) mixed ovarian tumor. Arkh Patol. 1983;45(7):76–9. Recinos-Money E, Escobar-Alfaro G, Contreras J, Zepeda-Castilla E, Parra-Torres C, Di Castro P. Ovarian adenosarcoma with elevated CA125 antigen. Case report and literature review. Cir Cir. 2008;76(1):71–5. Shakuntala P, Umadevi K, Usha A, Abhilasha N, Bafna U. Primary ovarian adenosarcoma with elevated Ca-125 levels and normal ascitic fluid cytology: a case report and review of literature. Ecancermedicalscience. 2012;6:284. Shintaku M, Mise Y. Mullerian adenosarcoma with a neuroectodermal component associated with an endometriotic cyst of the ovary: a case report. Pathol Int. 2012;62(4):271–5. Takeuchi K, Kitazawa S, Deguchi M, Maruo T. Adenofibromasarcoma originating from a mural nodule of ovarian serous cystadenoma. Eur J Gynaecol Oncol. 2005;26(5):511–3. Touraud JP, Lentz N, Dutronc Y, Mercier E, Sagot P, Lambert D. Umbilical cutaneous metastasis (or Sister Mary Joseph’s nodule) disclosing an ovarian adenocarcinoma. Gynecol Obstet Fertil. 2000;28(10):719–21. Yasuoka H, Tsujimoto M, Fujita S, Yamasaki T, Kashihara H, Nishio Y, et al. Coexistence of a clear cell adenocarcinoma and an adenosarcoma with a heterologous rhabdomyosarcoma in an endometriotic cyst of the ovary: a case study. Int J Gynecol Pathol. 2009;28(4):362–6. Valdez VA, Planas AT, Lopez VF, Goldberg M, Herrera NE. Adenosarcoma of uterus and ovary: a clinicopathologic study of two cases. Cancer. 1979;43(4):1439–47. Eichhorn JH, Young RH, Clement PB, Scully RE. Mesodermal (mullerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature. Am J Surg Pathol. 2002;26(10):1243–58. Gal D, Kerner H, Beck D, Peretz BA, Eyal A, Paldi E. Mullerian adenosarcoma of the uterine cervix. Gynecol Oncol. 1988;31(3):445–53. Kerner H, Lichtig C. Mullerian adenosarcoma presenting as cervical polyps: a report of seven cases and review of the literature. Obstet Gynecol. 1993;81(5 (Pt 1)):655–9. Patrelli TS, Gizzo S, Di Gangi S, Guidi G, Rondinelli M, Nardelli GB. Cervical Mullerian adenosarcoma with heterologous sarcomatous overgrowth: a fourth case and review of literature. BMC Cancer. 2011;11:236. Jones MW, Lefkowitz M. Adenosarcoma of the uterine cervix: a clinicopathological study of 12 cases. Int J Gynecol Pathol. 1995;14(3):223–9. Manoharan M, Azmi MA, Soosay G, Mould T, Weekes AR. Mullerian adenosarcoma of uterine cervix: report of three cases and review of literature. Gynecol Oncol. 2007;105(1):256–60. Seagle BL, Falter 2nd KJ, Lee SJ, Frimer M, Samuelson R, Shahabi S. Mullerian adenosarcoma of the cervix: report of two large tumors with sarcomatous overgrowth or heterologous elements. Gynecol Oncol Case Rep. 2014;9:7–10. Ali M, Fayemi AO. Mullerian adenosarcoma of uterine cervix. Report of a case with rapidly fatal outcome. Diagn Gynecol Obstet. 1980;2(2):135–8. Bagga R, Keepanasseril A, Srinivasan R, Dey P, Gainder S, Saha SC, et al. Adenosarcoma of the uterine cervix with heterologous elements: a case report and review of literature. Arch Gynecol Obstet. 2010;281(4):669–75. Bhandare D, Madiwale C, Kothari K, Pandit A, Kane S. Mullerian adenosarcoma of the uterine cervix. Indian J Pathol Microbiol. 2001;44(3):371–2. Charfi S, Kallel R, Mnif H, Ellouze S, Dhouib M, Guermazi M, et al. Mullerian adenosaroma of the cervix with sarcomatous overgrowth and heterologous elements presenting as a recurrent cervical polyp. Case Rep Obstet Gynecol. 2012;2012:358302. Comunoglu N, Comunoglu C, Bassullu N, Somunkiran A, Calay Z. Mullerian adenosarcoma with sarcomatous overgrowth of the cervix: unusual large polypoid mass. Ups J Med Sci. 2007;112(1):67–72. Duggal R, Nijhawan R, Aggarwal N, Sikka P. Mullerian adenosarcoma (heterologous) of the cervix with sarcomatous overgrowth: a case report with review of literature. J Gynecol Oncol. 2010;21(2):125–8. Edinger Jr DD, Safaii H, Tak W, Anderson B, Watring WG. Cervical mullerian adenosarcoma: case report. Eur J Gynaecol Oncol. 1982;3(2):69–73. Fayemi AO, Ali M, Braun EV. Mullerian adenosarcoma of the uterine cervix. Am J Obstet Gynecol. 1978;130(6):734–5. Feroze M, Aravindan KP, Thomas M. Mullerian adenosarcoma of the uterine cervix. Indian J Cancer. 1997;34(2):68–72. Fleming NA, Hopkins L, de Nanassy J, Senterman M, Black AY. Mullerian adenosarcoma of the cervix in a 10-year-old girl: case report and review of the literature. J Pediatr Adolesc Gynecol. 2009;22(4):e45–51. Garcia R, Troyas RG, Bercero EA. Mullerian adenosarcoma of the cervix: differential diagnosis, histogenesis and review of the literature. Pathol Int. 1995;45(11):890–4. Gast MJ, Radkins LV, Jacobs AJ, Gersell D. Mullerian adenosarcoma of the cervix with heterologous elements: diagnostic and therapeutic approach. Gynecol Oncol. 1989;32(3):381–4. Hino A, Hirose T, Seki K, Uehara H, Sano N. Adenosarcoma of the uterine cervix presenting as a cervical polyp. Pathol Int. 1998;48(8):649–52. Koshiyama M, Ueta M, Okamoto T, Yamamoto K. Mullerian adenosarcoma arising from the uterine cervix. Acta Obstet Gynecol Scand. 2004;83(3):315–6. Limaiem F, Bouraoui S, Azouz H, Lahmar A, Ben Fadhel C, Zouari F, et al. Adenosarcoma of the cervix with heterologous elements masquerading as a benign polyp: case report. Tunis Med. 2008;86(7):725–6. Niculescu M, Simionescu C, Novac L, Mogoanta L, Mindrila I. Adenosarcoma of the uterine cervix: positive and differential diagnosis. Rom J Morphol Embryol. 2007;48(1):79–82. Park HM, Park MH, Kim YJ, Chun SH, Ahn JJ, Kim CI, et al. Mullerian adenosarcoma with sarcomatous overgrowth of the cervix presenting as cervical polyp: a case report and review of the literature. Int J Gynecol Cancer. 2004;14(5):1024–9. Ramos P, Ruiz A, Carabias E, Pinero I, Garzon A, Alvarez I. Mullerian adenosarcoma of the cervix with heterologous elements: report of a case and review of the literature. Gynecol Oncol. 2002;84(1):161–6. Rossi G, Cavazza A, Longo L, Maiorana A. Localized pleural metastatic adenosarcoma of the uterine cervix mimicking a malignant solitary fibrous tumour: CD10 has no value in differential diagnosis. Histopathology. 2002;41(1):82–3. Roth LM, Pride GL, Sharma HM. Mullerian adenosarcoma of the uterine cervix with heterologous elements: a light and electron microscopic study. Cancer. 1976;37(4):1725–36. Tang CK, Toker C, Harriman B. Mullerian adenosarcoma of the uterine cervix. Hum Pathol. 1981;12(6):579–81. Tomaszewski A, Michels JJ. Rare case of a cervix of uterus adenosarcome reported on a primipara 29 years old woman. Ann Pathol. 2013;33(3):222–4. Anderson J, Behbakht K, De Geest K, Bitterman P. Adenosarcoma in a patient with vaginal endometriosis. Obstet Gynecol. 2001;98(5 Pt 2):964–6. Wang Y, Huang YW, Li YF. Primary vaginal sarcoma: experience of a regional cancer center in China. J Obstet Gynaecol Res. 2015;41(9):1463–8. Han X, Leng J, Guo L, Xiang Y, Lang J. Vaginal adenosarcoma arising from refractory endometriosis: a case report. Aust N Z J Obstet Gynaecol. 2010;50(6):574–6. Judson PL, Temple AM, Fowler Jr WC, Novotny DB, Funkhouser Jr WK. Vaginal adenosarcoma arising from endometriosis. Gynecol Oncol. 2000;76(1):123–5. Toyoshima M, Akahira J, Moriya T, Hayakawa S, Yaegashi N. Primary vaginal adenosarcoma with sarcomatous overgrowth. Gynecol Oncol. 2004;95(3):759–61. Lyle P, Evans R, Jarboe E, Fong D, Behbakht K, Davidson S, et al. Biphasic tumors of the female genital tract. Oncology (Williston Park). 2005;19(9):1178. 83, 88, 90, 95–6 passim. de Jonge MJ, van Dam PA, Van Marck E, Prove A, van Oosterom AT. Primary extrauterine mullerian adenosarcoma of the peritoneum. Gynecol Oncol. 1995;57(1):126–30. Dincer AD, Timmins P, Pietrocola D, Fisher H, Ambros RA. Primary peritoneal mullerian adenosarcoma with sarcomatous overgrowth associated with endometriosis: a case report. Int J Gynecol Pathol. 2002;21(1):65–8. Kanngurn S, Somran J, Art-Ong C, Lamlertthon W, Porncharoenpong S. Primary peritoneal adenosarcoma with stromal overgrowth and fetal type cartilage: a case report and literature review. J Med Assoc Thai. 2005;88(6):849–54. Kar R, Verma SK, Papa D, Sylvia MT. Extrauterine adenosarcoma arising in omental endometriosis: rare site of occurrence of a rare tumor. Indian J Pathol Microbiol. 2014;57(4):640–1. Karateke A, Kahramanoglu I, Bilgic R. Extragenital mullerian adenosarcoma in the pouch of douglas. Balkan Med J. 2014;31(1):100–4. Kato N, Zhe J, Endoh Y, Motoyama T. Extrauterine Mullerian adenosarcoma of the peritoneum with an extensive rhabdomyosarcomatous element and a marked myxoid change. Pathol Int. 2000;50(4):347–51. Kerner H, Lichtig C, Beck D. Extrauterine mullerian adenosarcoma of the peritoneal mesothelium: a clinicopathologic and electron microscopic study. Obstet Gynecol. 1989;73(3 Pt 2):510–3. Murugasu A, Miller J, Proietto A, Millar E. Extragenital mullerian adenosarcoma with sarcomatous overgrowth arising in an endometriotic cyst in the pouch of Douglas. Int J Gynecol Cancer. 2003;13(3):371–5. Ostor AG, Nirenberg A, Ashdown ML, Murphy DJ. Extragenital adenosarcoma arising in the pouch of Douglas. Gynecol Oncol. 1994;53(3):373–5. Patrelli TS, Silini EM, Gizzo S, Berretta R, Franchi L, Thai E, et al. Extragenital Mullerian adenosarcoma with pouch of Douglas location. BMC Cancer. 2011;11:171. Raffaelli R, Piazzola E, Zanconato G, Fedele L. A rare case of extrauterine adenosarcoma arising in endometriosis of the rectovaginal septum. Fertil Steril. 2004;81(4):1142–4. Thylan S. Primary extrauterine mullerian adenosarcoma of the peritoneum. Gynecol Oncol. 1996;60(2):333. Toral JA. Extraendometrial mullerian adenosarcoma. Philipp J Obstet Gynecol. 1998;22(3):87–97. Visvalingam S, Jaworski R, Blumenthal N, Chan F. Primary peritoneal mesodermal adenosarcoma: report of a case and review of the literature. Gynecol Oncol. 2001;81(3):500–5. Yang C, Oh HK, Kim D. Mullerian adenosarcoma arising from rectal endometriosis. Ann Coloproctol. 2014;30(5):232–6. Russell P, Slavutin L, Laverty CR, Cooper-Booth J. Extrauterine mesodermal (mullerian) adenosarcoma. A case report. Pathology. 1979;11(3):557–60. Lazar RI, Straja T, Bratucu B. Uterine adenosarcoma metastasizing to the retroperitoneum. The impact of vascular involvement. J Med Life. 2012;5(2):145–8. Marco V, Forcada P. Mesonephric adenosarcoma of the renal pelvis with heterologous elements. Am J Surg Pathol. 1985;9(8):610–4. Michal M, Hes O, Bisceglia M, Simpson RH, Spagnolo DV, Parma A, et al. Mixed epithelial and stromal tumors of the kidney. A report of 22 cases. Virchows Arch. 2004;445(4):359–67. Picken MM, Curry JL, Lindgren V, Clark JI, Eble JN. Metanephric adenosarcoma in a young adult: morphologic, immunophenotypic, ultrastructural, and fluorescence in situ hybridization analyses: a case report and review of the literature. Am J Surg Pathol. 2001;25(11):1451–7. Sameshima N, Marutsuka K, Tsukino H, Kamoto T, Kono S, Asada Y. So-called ‘adenosarcoma’ of the kidney a novel adult renal tumor with a cystic appearance. Pathol Int. 2011;61(5):313–8. Su T, Yan F, Zhu P. Metanephric adenosarcoma: a rare case with immunohistochemistry and molecular analysis. Diagn Pathol. 2014;9:179. Vara AR, Ruzics EP, Moussabeck O, Martin DC. Endometrioid adenosarcoma of the bladder arising from endometriosis. J Urol. 1990;143(4):813–5. Volkov VP, Lazdin OA, Sadikov ID. Adenosarcoma of the liver in patient with liver cirrhosis. Klin Med (Mosk). 1979;57(3):105–7. N’Senda P, Wendum D, Balladur P, Dahan H, Tubiana JM, Arrive L. Adenosarcoma arising in hepatic endometriosis. Eur Radiol. 2000;10(8):1287–9. Jelovsek JE, Winans C, Brainard J, Falcone T. Endometriosis of the liver containing mullerian adenosarcoma: case report. Am J Obstet Gynecol. 2004;191(5):1725–7. Yang F, Yang KX, Yao XY, Gong J, Song B. Adenosarcoma arising in abdominal scar endometriosis: report of a case. Zhonghua Bing Li Xue Za Zhi. 2008;37(9):643–4. Milam MR, Atkinson JB, Currie JL. Adenosarcoma arising in inguinal endometriosis. Obstet Gynecol. 2006;108(3 Pt 2):753–5. Kondi-Pafiti A, Spanidou-Carvouni H, Papadias K, Hatzistamou-Kiari I, Kontogianni K, Liapis A, et al. Malignant neoplasms arising in endometriosis: clinicopathological study of 14 cases. Clin Exp Obstet Gynecol. 2004;31(4):302–4. Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, Robboy SJ. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol. 2001;20(2):133–9. Higashiura Y, Kajihara H, Shigetomi H, Kobayashi H. Identification of multiple pathways involved in the malignant transformation of endometriosis (review). Oncol Lett. 2012;4(1):3–9. Akhavan A, Akhavan Tafti M, Aghili F, Navabii H. Uterine adenosarcoma in a patient with history of breast cancer and long-term tamoxifen consumption. BMJ Case Rep. 2012;2012. Arenas M, Rovirosa A, Hernandez V, Ordi J, Jorcano S, Mellado B, et al. Uterine sarcomas in breast cancer patients treated with tamoxifen. Int J Gynecol Cancer. 2006;16(2):861–5. Arici DS, Aker H, Yildiz E, Tasyurt A. Mullerian adenosarcoma of the uterus associated with tamoxifen therapy. Arch Gynecol Obstet. 2000;264(2):105–7. Farhat F, Fakhruddine N. A case of synchronous relapse of breast cancer and uterine mullerian adenosarcoma post tamoxifen in a premenopausal woman. Eur J Gynaecol Oncol. 2008;29(1):95–7. Jagavkar RS, Shakespeare TP, Stevens MJ. Endometrial adenosarcoma with adjuvant tamoxifen therapy for primary breast carcinoma. Australas Radiol. 1998;42(2):157–8. Jessop FA, Roberts PF. Mullerian adenosarcoma of the uterus in association with tamoxifen therapy. Histopathology. 2000;36(1):91–2. Le Bouedec G, Penault-Llorca F, de Latour M, Tortochaux J, Dauplat J. Mixed mullerian tumours of the endometrium. About four cases developed on tamoxifen treatment. Gynecol Obstet Fertil. 2003;31(9):733–8. Martin-Loeches M, Rius J, Orti RM. Uterine sarcoma associated with tamoxifen use: case report. Eur J Gynaecol Oncol. 2003;24(2):202–3. Soh E, Eleti A, Jimenez-Linan M, Arends MJ, Latimer J, Sala E. Magnetic resonance imaging findings of tamoxifen-associated uterine Mullerian adenosarcoma: a case report. Acta Radiol. 2008;49(7):848–51. Chung YW, Bae HS, Han SI, Song JY, Kim IS, Kang JS. Endometrial mullerian adenosarcoma after toremifene treatment in breast cancer patients: a case report. J Gynecol Oncol. 2010;21(4):269–72. Kennedy MM, Baigrie CF, Manek S. Tamoxifen and the endometrium: review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology. Int J Gynecol Pathol. 1999;18(2):130–7. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88. Press MF, Scully RE. Endometrial “sarcomas” complicating ovarian thecoma, polycystic ovarian disease and estrogen therapy. Gynecol Oncol. 1985;21(2):135–54. Lai CR, Hsu CY, Li AF. Uterine adenosarcoma detected by conventional papanicolaou smear: a case report with emphasis on integrating the immunocytochemical staining. Diagn Cytopathol. 2012;40(10):920–4. Pasternak S, MacIntosh R. Uterine adenosarcoma detected by Papanicolaou smear: a case report. Diagn Cytopathol. 2006;34(7):495–8. Shah SH, Jagannathan JP, Krajewski K, O’Regan KN, George S, Ramaiya NH. Uterine sarcomas: then and now. AJR Am J Roentgenol. 2012;199(1):213–23. Santos P, Cunha TM. Uterine sarcomas: clinical presentation and MRI features. Diagn Interv Radiol. 2015;21(1):4–9. Takeuchi M, Matsuzaki K, Yoshida S, Kudo E, Bando Y, Hasebe H, et al. Adenosarcoma of the uterus: magnetic resonance imaging characteristics. Clin Imaging. 2009;33(3):244–7. Tirumani SH, Ojili V, Shanbhogue AK, Fasih N, Ryan JG, Reinhold C. Current concepts in the imaging of uterine sarcoma. Abdom Imaging. 2013;38(2):397–411. McCluggage WG. Mullerian adenosarcoma of the female genital tract. Adv Anat Pathol. 2010;17(2):122–9. Pinto A, Howitt B. Uterine adenosarcoma. Arch Pathol Lab Med. 2016;140(3):286–90. Friedlander ML, Covens A, Glasspool RM, Hilpert F, Kristensen G, Kwon S, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S78–82. Howitt BE, Quade BJ, Nucci MR. Uterine polyps with features overlapping with those of Mullerian adenosarcoma: a clinicopathologic analysis of 29 cases emphasizing their likely benign nature. Am J Surg Pathol. 2015;39(1):116–26. Soslow RA, Ali A, Oliva E. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases. Am J Surg Pathol. 2008;32(7):1013–21. Van Mieghem T, Abeler VM, Moerman P, Verbist L, Vergote I, Amant F. CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma. Gynecol Oncol. 2005;99(2):493–6. Mikami Y, Hata S, Kiyokawa T, Manabe T. Expression of CD10 in malignant mullerian mixed tumors and adenosarcomas: an immunohistochemical study. Mod Pathol. 2002;15(9):923–30. Aggarwal N, Bhargava R, Elishaev E. Uterine adenosarcomas: diagnostic use of the proliferation marker Ki-67 as an adjunct to morphologic diagnosis. Int J Gynecol Pathol. 2012;31(5):447–52. Abeler VM, Nenodovic M. Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases. Int J Gynecol Pathol. 2011;30(3):236–43. D’Angelo E, Prat J. Diagnostic use of immunohistochemistry in uterine mesenchymal tumors. Semin Diagn Pathol. 2014;31(3):216–22. Erdogan G, Bassorgun CI, Pestereli HE, Simsek T, Karaveli S. C-kit protein expression in uterine and ovarian mesenchymal tumours. APMIS. 2007;115(3):204–9. Kildal W, Pradhan M, Abeler VM, Kristensen GB, Danielsen HE. Beta-catenin expression in uterine sarcomas and its relation to clinicopathological parameters. Eur J Cancer. 2009;45(13):2412–7. Ioffe YJ, Li AJ, Walsh CS, Karlan BY, Leuchter R, Forscher C, et al. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol. 2009;115(3):466–71. •• Howitt BE, Sholl LM, Dal Cin P, Jia Y, Yuan L, MacConaill L, et al. Targeted genomic analysis of Mullerian adenosarcoma. J Pathol. 2015;235(1):37–49. First targeted genomic analysis of uterine adenosarcoma, showing mutations in the PTEN/AKT/PI3K pathway in ∼ 70% of patients. •• Howitt BE, Dal Cin P, Nucci MR, Quade BJ. Involvement of Chromosome 8 in Mullerian Adenosarcoma. Int J Gynecol Pathol. 2016. Cytogenetic characterization of uterine adenosarcomas, with first description of chromosome 8 abnormalities in 71% of cases. Swisher EM, Gown AM, Skelly M, Ek M, Tamimi HK, Cain JM, et al. The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecol Oncol. 1996;60(1):81–8. Kerner H, Levy R, Friedman M, Beck D. Uterine and extrauterine Mullerian adenosarcoma: a histopathologic and flow cytometric study. Int J Gynecol Cancer. 1997;7(4):318–24. Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L, Moerman P, et al. ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecol Oncol. 2004;95(3):583–7. Hoang LN, Ali RH, Lau S, Gilks CB, Lee CH. Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas. Int J Gynecol Pathol. 2014;33(5):483–91. Zaloudek CJ, Norris HJ. Adenofibroma and adenosarcoma of the uterus: a clinicopathologic study of 35 cases. Cancer. 1981;48(2):354–66. Corrigendum to “FIGO staging for uterine sarcomas” [Int J Gynaecol Obstet. 2009;104(3):179]. Int J Gynaecol Obstet. 2009; 106(3):277. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. The impact of tumor morcellation during surgery on the outcomes of patients with apparently early low-grade endometrial stromal sarcoma of the uterus. Ann Surg Oncol. 2011;18(12):3453–61. Park JY, Park SK, Kim DY, Kim JH, Kim YM, Kim YT, et al. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol. 2011;122(2):255–9. Han XY, Xiang Y, Guo LN, Sheng K, Wan XR, Huang HF, et al. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 9 cases. Zhonghua Zhong Liu Za Zhi. 2010;32(1):44–7. Koh WJ, Greer BE, Abu-Rustum N, Apte SM, Campos SM, Cho KR, et al. NCCN Clinical Practure Guidelines in Oncology Uterine Neoplams Version 2.2015: National Comprehensive Cancer Network; 2015 [cited 2015 9/15/2015]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/uterineneoplams.pdf. Michener CM, Simon NL. Ovarian conservation in a woman of reproductive age with mullerian adenosarcoma. Gynecol Oncol. 2001;83(2):424–7. Ozmen B, Uzum N, Unlu C, Ortac F, Ataoglu O. Surgical conservation of both ovaries in an adolescent with uterine mullerian adenosarcoma: a case report. J Minim Invasive Gynecol. 2007;14(3):375–8. Klopp A, Smith BD, Alektiar K, Cabrera A, Damato AL, Erickson B, et al. The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2014;4(3):137–44. Reed NS, Mangioni C, Malmstrom H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44(6):808–18. Viswanathan AN, Lee LJ, Eswara JR, Horowitz NS, Konstantinopoulos PA, Mirabeau-Beale KL, et al. Complications of pelvic radiation in patients treated for gynecologic malignancies. Cancer. 2014;120(24):3870–83. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol: Off J Am Soc Clin Oncol. 2007;25(19):2755–63. Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109(3):329–34. Hensley ML, Ishill N, Soslow R, Larkin J, Abu-Rustum N, Sabbatini P, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol. 2009;112(3):563–7. Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer. 2013;119(8):1555–61. Kanjeekal S, Chambers A, Fung MF, Verma S. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol. 2005;97(2):624–37. Odunsi K, Moneke V, Tammela J, Ghamande S, Seago P, Driscoll D, et al. Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up. Int J Gynecol Cancer. 2004;14(4):659–64. Huang GS, Arend RC, Sakaris A, Hebert TM, Goldberg GL. Extragenital adenosarcoma: a case report, review of the literature, and management discussion. Gynecol Oncol. 2009;115(3):472–5. Guidozzi F, Smith T, Koller AB, Reinecke L. Management of uterine Mullerian adenosarcoma with extrauterine metastatic deposits. Gynecol Oncol. 2000;77(3):464–6. Yamagami W, Susumu N, Ninomiya T, Kuwahata M, Takigawa A, Nomura H, et al. A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma. Mol Clin Oncol. 2014;2(4):591–5. Verschraegen CF, Arias-Pulido H, Lee SJ, Movva S, Cerilli LA, Eberhardt S, et al. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol. 2012;23(3):785–90. del Carmen MG, Lovett D, Goodman A. A case of Mullerian adenosarcoma of the uterus treated with liposomal doxorubicin. Gynecol Oncol. 2003;88(3):456–8. Maeda M, Mabuchi S, Matsumoto Y, Hisamatsu T, Ohashi H, Kimura T. Activity of pegylated liposomal doxorubicin for extragenital mullerian adenosarcoma with sarcomatous overgrowth: a case report and a review of the literature. Eur J Gynaecol Oncol. 2011;32(5):542–6. Schroeder BA, Rodler ET, Loggers ET, Pollack SM, Jones RL. Clinical benefit of trabectedin in uterine adenosarcoma. Med Oncol. 2013;30(2):501. Roman LD, Mitchell MF, Tornos C, Glover A, Kavanagh JJ. Dedifferentiated extrauterine adenosarcoma responsive to chemotherapy. Gynecol Oncol. 1993;49(3):389–94. Hines BJ, Porges RF, Mittal K, Muggia FM, Curtin JP. Use of medroxyprogesterone acetate in the treatment of Mullerian adenosarcoma: a case report. Gynecol Oncol. 2002;85(1):192–5. Lee SJ, Bae JH, Kim DC, Park JS, Namkoong SE. Oral progesterone treatment in a young woman with mullerian adenosarcoma whose ovary was preserved: a case report. Int J Gynecol Cancer. 2010;20(7):1222–4. Gruber TJ, Fabiano AJ, Deeb G, Lele SB, Fenstermaker RA. Intracranial meningiomas in patients with uterine sarcoma treated with long-term megestrol acetate therapy. World Neurosurg. 2011;76(5):477.e16–20. Tasaka N, Matsumoto K, Satoh T, Minaguchi T, Onuki M, Ochi H, et al. Therapeutic effect of dienogest on adenosarcoma arising from endometriosis: a case report. Springerplus. 2013;2:618. Moinfar F, Azodi M, Tavassoli FA. Uterine sarcomas. Pathology. 2007;39(1):55–71. Author information Authors and Affiliations Corresponding author Ethics declarations Conflict of Interest Michael J. Nathenson, Vinod Ravi, Nicole Fleming, Wei-Lien Wang, and Anthony Conley declare that they have no conflict of interest. Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors. Additional information This article is part of the Topical Collection on Sarcomas Rights and permissions About this article Cite this article Nathenson, M.J., Ravi, V., Fleming, N. et al. Uterine Adenosarcoma: a Review. Curr Oncol Rep 18, 68 (2016). https://doi.org/10.1007/s11912-016-0552-7 Published: DOI: https://doi.org/10.1007/s11912-016-0552-7